Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1539-1548

  Iskedjian, Michael ^a   Walker, John H ^a,b   Bereza, Basil G ^a   Le Melledo, Jean Michel ^c   Einarson, Thomas R ^a,d  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b BROCK UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Cost effectiveness; Economics; Escitalopram; Generalized anxiety disorder

Indexed keywords

CLONAZEPAM; ESCITALOPRAM; PAROXETINE;

ARTICLE; CANADA; COMORBIDITY; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GENERALIZED ANXIETY DISORDER; HEALTH SERVICE; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; PRIMARY MEDICAL CARE; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYMPTOM;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CANADA; CHRONIC DISEASE; CITALOPRAM; CONFIDENCE INTERVALS; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MONTE CARLO METHOD; PAROXETINE; PRIMARY HEALTH CARE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 44349112922     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X297277     Document Type: Article

References (24)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). Washington: American Psychiatric Association, 1994
2. Kessler R, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 2005;35:1073-82
3. Wittchen H-U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162-71
4. Greenburg P, Sisitky T, Kessler R, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-35
5. Canadian Clinical Practice Guidelines. Management of anxiety disorders: generalized anxiety disorder. Can J Psychiatry 2006;51:51-5S
6. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association, 2005:1923
7. Goodman W, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161-7
8. Baldwin D, Reines E, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92
9. Bielski R, Bose A, Chang C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-9
10. CADTH. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. Ottawa: Canadian Agency for Drug and Technologies in Health, 2006
11. Maier W, Buller R, Philipp M, et al. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord 1988;14:61-8
12. Wan G, Zhang H, Tedeschi M, et al. Estimation of symptom-free days in generalized anxiety disorder. Curr Med Res Opin 2006;22:587-91
13. Ministry of Health and Long-Term Care. Schedule of Benefits for Physician Services under the Health Insurance Act. Toronto: Ontario Ministry of Health and Long-Term Care, 2007
14. StatCan. Average hourly wages of employees by selected characteristics and profession, unadjusted data, by province (monthly). Available at: http://www.statcan.ca/ [Accessed: 2007 Dec 20]
15. Stinnett A, Paltiel D. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997;17:483-9
16. Guest J, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom. Eur J Health Econ 2005;6:136-45
17. Issakidis C, Sanderson K, Corry J, et al. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders. Psychol Med 2004;34:19-35
18. Heuzenroeder L, Donnelly M, Haby M, et al. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Aust N Z J Psychiatry 2004;38:602-12
19. Koerner N, Dugas M, Savard P, et al. The economic burden of anxiety disorders in Canada. Can Psychol 2004;45:191-201
20. Stein M, Roy-Byrne P, Craske M, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164-70
21. Wetherell J, Thorp S, Patterson T, et al. Quality of life in geriatric generalized anxiety disorder: a preliminary investigation. J Psychiatr Res 2004;38:305-12
22. Piccinelli M. Comorbidity of depression and generalized anxiety: is there any distinct boundary? Curr Opin Psychiatry 1998;11:57-60
23. Jacobi F, Wittchen H, Holting C, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004;34:597-611
24. Dubovsky S. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990;51:3-10